TSHR; OPRD1; | |
DRD3; HCAR2; HTR2C; | |
PTPN1; | |
ACHE; | |
TDP1; PKM; HSD17B1; NOX4; ALOX15; USP2; TNKS; TNKS2; | |
CFTR; | |
GSK3B; SYK; FLT3; CDK6; CSNK2A1; | |
AR; | |
PPARA; PPARD; | |
ESR2; ESR1; | |
MAOA; PTGS2; XDH; | |
BACE1; | |
HIF1A; TP53; | |
VCP; | |
ABCG2; ABCC1; | |
NPC1; MCL1; MAPT; THPO; TTR; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Endoplasmic reticular retrotranslocon family | VCP | Transitional endoplasmic reticulum ATPase | P55072 | CHEMBL1075145 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.602E-10 | 8.514E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.779E-09 | 1.435E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.154E-09 | 1.675E-06 | CFTR, DRD3, HCAR2, HIF1A, NPC1, PTGS2, SYK, TNKS, TNKS2 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.458E-09 | 4.181E-06 | CDK6, CFTR, DRD3, HCAR2, HIF1A, HTR2C, NPC1, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.577E-08 | 6.480E-06 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2, VCP |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.751E-08 | 7.060E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 4.625E-08 | 1.481E-05 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.171E-08 | 2.372E-05 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 1.022E-07 | 2.748E-05 | AR, CDK6, CFTR, CYP1B1, ESR1, GSK3B, NOX4, PKM, PPARD, PTGS2, TP53, TSHR |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 5.776E-07 | 1.187E-04 | AR, CDK6, CSNK2A1, DRD3, ESR1, FLT3, HIF1A, PPARD, PTGS2, SYK, THPO, TSHR |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.047E-06 | 1.982E-04 | CYP1B1, GSK3B, HCAR2, MAPT, MCL1, NOX4, PTGS2, TP53, VCP, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.402E-06 | 2.500E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.924E-06 | 3.223E-04 | AR, CYP19A1, ESR1 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 2.070E-06 | 3.389E-04 | MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 2.245E-06 | 3.477E-04 | ALOX15, AR, FLT3, HTR2C, NOX4, PTPN1, SYK, THPO, XDH |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.222E-06 | 3.477E-04 | ABCG2, ACHE, CSNK2A1, ESR1, ESR2, FLT3, MAPT, MCL1, PKM, PTGS2, TP53, TTR, USP2, VCP, XDH |
BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 2.713E-06 | 3.991E-04 | AR, CSNK2A1, DRD3, ESR1, ESR2, GSK3B, HIF1A, MAPT, MCL1, NPC1, PPARA, PPARD, PTGS2, PTPN1, TNKS, TNKS2, TP53, USP2, XDH |
MF | GO:0005488; binding | GO:0019904; protein domain specific binding | 3.475E-06 | 4.905E-04 | AR, CFTR, DRD3, HIF1A, MAPT, MCL1, PPARA, SYK, TP53, VCP |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.228E-06 | 5.791E-04 | HIF1A, OPRD1, PPARD, PTGS2, TP53 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.307E-06 | 7.133E-04 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 7.223E-06 | 9.418E-04 | AR, ESR1, GSK3B, PPARA, TP53 |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.021E-05 | 1.263E-03 | ALOX15, DRD3, GSK3B, HIF1A, MAPT, NOX4, TNKS, TNKS2, TP53 |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.032E-05 | 1.270E-03 | ABCG2, ACHE, AR, BACE1, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, ESR1, ESR2, FLT3, GSK3B, HIF1A, MAOA, MAPT, MCL1, NOX4, NPC1, PKM, PPARA, PPARD, PTGS2, PTPN1, SYK, TDP1, TNKS, TNKS2, TP53, VCP, XDH |
BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 1.040E-05 | 1.272E-03 | CFTR, CYP19A1, HCAR2, HIF1A, PPARD |
BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 1.167E-05 | 1.404E-03 | CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.302E-05 | 1.550E-03 | ALOX15, ESR1, GSK3B, MAPT, TP53, VCP |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.526E-05 | 1.767E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.590E-05 | 1.803E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.590E-05 | 1.803E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.025E-05 | 2.194E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 2.159E-05 | 2.328E-03 | ABCG2, ACHE, AR, FLT3, HIF1A, MAPT, MCL1, PPARD, PTGS2, TP53, TTR, XDH |
BP | GO:0008152; metabolic process | GO:0045935; positive regulation of nucleobase-containing compound metabolic process | 2.282E-05 | 2.435E-03 | AR, DRD3, ESR1, ESR2, HIF1A, NOX4, PPARA, PPARD, PTPN1, TNKS, TNKS2, TP53, TSHR, VCP |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.622E-05 | 2.719E-03 | HIF1A, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.959E-05 | 3.011E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 3.072E-05 | 3.097E-03 | ALOX15, PPARA, PPARD, TP53 |
BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 3.072E-05 | 3.097E-03 | GSK3B, MAPT, MCL1, TP53 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.175E-05 | 3.100E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.175E-05 | 3.100E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.175E-05 | 3.100E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.175E-05 | 3.100E-03 | CYP1A2, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 3.292E-05 | 3.172E-03 | CFTR, GSK3B, NOX4, PKM, PTGS2, TP53, TSHR |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 3.323E-05 | 3.188E-03 | CYP1B1, HIF1A, PTGS2 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.424E-05 | 3.270E-03 | AR, ESR1, ESR2, PPARA, PPARD |
MF | GO:0005488; binding | GO:0005102; receptor binding | 3.444E-05 | 3.275E-03 | AR, DRD3, ESR1, ESR2, FLT3, HIF1A, MAPT, PTPN1, SYK, THPO, TP53, TTR, VCP |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 3.716E-05 | 3.488E-03 | CYP19A1, CYP3A4, ESR1 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 3.716E-05 | 3.488E-03 | MAPT, PTPN1, TP53 |
BP | GO:0009987; cellular process | GO:0070372; regulation of ERK1 and ERK2 cascade | 3.948E-05 | 3.628E-03 | ALOX15, HTR2C, NOX4, PTPN1, SYK, THPO |
MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 3.937E-05 | 3.628E-03 | AR, CSNK2A1, ESR1, GSK3B |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 5.074E-05 | 4.547E-03 | ABCC1, ALOX15, SYK |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.283E-05 | 4.639E-03 | CYP1A1, CYP3A4 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.590E-05 | 4.830E-03 | CSNK2A1, HIF1A, MAPT |
BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 5.674E-05 | 4.883E-03 | CYP1A1, CYP1B1, PPARD, TTR |
BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 5.781E-05 | 4.936E-03 | CSNK2A1, CYP1B1, DRD3, ESR1, GSK3B, MAPT, PPARA, PTGS2, PTPN1, TNKS, TP53 |
BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 5.847E-05 | 4.973E-03 | DRD3, HTR2C, NPC1, OPRD1, USP2 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 7.009E-05 | 5.803E-03 | HIF1A, MCL1, PTGS2, PTPN1 |
BP | GO:0065007; biological regulation | GO:0043085; positive regulation of catalytic activity | 7.234E-05 | 5.928E-03 | ESR1, FLT3, GSK3B, HIF1A, MAPT, NOX4, PTPN1, SYK, TNKS, TSHR, VCP, XDH |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 7.395E-05 | 6.031E-03 | ACHE, CSNK2A1, FLT3, MAPT, PKM, PPARA, PTPN1, SYK, TSHR, VCP |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 7.913E-05 | 6.279E-03 | DRD3, PPARA, TP53, USP2 |
BP | GO:0071840; cellular component organization or biogenesis | GO:0070841; inclusion body assembly | 7.913E-05 | 6.279E-03 | MAPT, VCP |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.913E-05 | 6.279E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.913E-05 | 6.279E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 8.685E-05 | 6.803E-03 | ALOX15, PTGS2, SYK |
BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 1.093E-04 | 8.309E-03 | ALOX15, FLT3, GSK3B, HIF1A, MCL1, PTGS2, TP53 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.106E-04 | 8.309E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:1903715; regulation of aerobic respiration | 1.106E-04 | 8.309E-03 | HIF1A, VCP |
MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 1.106E-04 | 8.309E-03 | PPARA, TP53 |
MF | GO:0005488; binding | GO:0070324; thyroid hormone binding | 1.106E-04 | 8.309E-03 | PKM, TTR |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 1.106E-04 | 8.309E-03 | ABCC1, ABCG2 |
BP | GO:0008152; metabolic process | GO:0072521; purine-containing compound metabolic process | 1.122E-04 | 8.368E-03 | ABCG2, HTR2C, PKM, TTR, VCP, XDH |
BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1.135E-04 | 8.435E-03 | CSNK2A1, MAPT, PTGS2, VCP, XDH |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.154E-04 | 8.548E-03 | CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0008152; metabolic process | GO:0090407; organophosphate biosynthetic process | 1.341E-04 | 9.736E-03 | ACHE, ALOX15, CSNK2A1, HTR2C, PKM, PPARD, PTGS2 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.402E-09 | 4.491E-07 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 9.010E-08 | 5.946E-06 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.547E-06 | 6.724E-05 | AR; GSK3B; CDK6; FLT3; PTGS2; HIF1A; TP53; PPARD |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.926E-06 | 6.356E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.100E-06 | 4.840E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.545E-05 | 3.400E-04 | PKM; FLT3; TP53; HIF1A |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.173E-05 | 4.098E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.103E-05 | 6.736E-04 | ABCC1; CDK6; CYP1B1; PTGS2; TP53; MCL1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.163E-04 | 1.396E-03 | MAOA; ALOX15; HTR2C; PTGS2 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.423E-04 | 1.445E-03 | GSK3B; TP53; ESR1; HIF1A |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.733E-05 | 6.160E-04 | CYP1A2; ALOX15; CYP3A4 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.489E-04 | 2.879E-03 | PKM; MAOA; HSD17B1; CYP1A2; ALOX15; CYP1A1; PTGS2; CYP3A4; CYP19A1; XDH |
hsa05162 | Measles_Homo sapiens_hsa05162 | 2.455E-04 | 2.315E-03 | GSK3B; CDK6; CSNK2A1; TP53 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.895E-04 | 2.548E-03 | GSK3B; CSNK2A1; TP53; PPARD |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.322E-04 | 1.445E-03 | ABCC1; CFTR; ABCG2 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 9.769E-04 | 5.748E-03 | GSK3B; CDK6; SYK; TP53; MCL1 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.695E-04 | 3.759E-03 | GSK3B; ESR1; ESR2 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.217E-04 | 3.275E-03 | CYP1A2; CYP1A1; CYP3A4 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.027E-04 | 3.686E-03 | MAOA; CYP1A2; CYP3A4 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.030E-03 | 5.748E-03 | HCAR2; PPARA; CFTR; TSHR |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.089E-03 | 5.748E-03 | GSK3B; SYK; CSNK2A1; TP53 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.150E-03 | 5.836E-03 | CDK6; PKM; SYK; TP53 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.056E-03 | 5.748E-03 | GSK3B; AR; TP53 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.561E-04 | 5.748E-03 | CDK6; PTGS2; TP53 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.467E-04 | 3.759E-03 | CYP3A4; CFTR; ABCG2 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.892E-03 | 8.918E-03 | PTPN1; GSK3B; PPARA |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.199E-03 | 5.862E-03 | SYK; CSNK2A1; PTGS2 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.434E-03 | 1.374E-02 | OPRD1; HTR2C; DRD3; TSHR |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.488E-03 | 1.132E-02 | OPRD1; ABCC1; TP53 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 3.053E-03 | 1.300E-02 | GSK3B; MAOA; DRD3 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.327E-03 | 1.372E-02 | GSK3B; PPARA; TP53 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.730E-03 | 1.201E-02 | GSK3B; CDK6; TP53 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 6.379E-03 | 2.339E-02 | BACE1; GSK3B; MAPT |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.069E-02 | 3.003E-02 | TP53; HIF1A; ESR1 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.111E-03 | 2.305E-02 | GSK3B; TP53 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 7.057E-03 | 2.389E-02 | PTGS2; TSHR |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 7.057E-03 | 2.389E-02 | CDK6; TP53 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.411E-03 | 2.889E-02 | CDK6; TP53 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.303E-03 | 2.410E-02 | FLT3; PPARD |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.592E-03 | 2.700E-02 | GSK3B; TP53 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.691E-03 | 2.907E-02 | CDK6; TP53 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 6.815E-03 | 2.389E-02 | GSK3B; TP53 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.176E-02 | 3.103E-02 | GSK3B; SYK |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.115E-02 | 3.066E-02 | CDK6; TP53 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.176E-02 | 3.103E-02 | CDK6; TP53 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.592E-03 | 2.700E-02 | ALOX15; PTGS2 |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.676E-02 | 4.255E-02 | THPO; FLT3 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 4.811E-03 | 1.868E-02 | CYP3A4; XDH |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.055E-02 | 3.003E-02 | PPARA; PPARD |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.055E-02 | 3.003E-02 | CDK6; TP53 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.206E-02 | 3.123E-02 | PTPN1; CSNK2A1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.929E-05 | 6.736E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
NA: NA | Primary insomnia | NA | HTR2C |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1; HCAR2 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PPARD; PTGS2; HCAR2 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; HTR2C |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; ACHE; CYP3A4; MAOA; HTR2C |
NA: NA | Upper abdominal bloating | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; HTR2C; HTR2C |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; HTR2C |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGS2; MAPT |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; OPRD1; PTGS2; PTGS2; PTGS2; PTGS2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
C00-D49: Neoplasms | AML | NA | FLT3 |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; HIF1A; SYK; TP53; FLT3; FLT3; ACHE; ESR1; ESR1; PTGS2; MCL1; CSNK2A1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; DRD3 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; MAOA; HTR2C |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; FLT3; PKM |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; HCAR2 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
NA: NA | Menopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
C00-D49: Neoplasms | CLL | NA | FLT3 |
NA: NA | Dyslipidemia | NA | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Multiple myeloma | C90 | VCP |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2C |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
NA: NA | Male hypogonadism | NA | AR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; HTR2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; HTR2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; ABCC1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; PTGS2 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; HCAR2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PTGS2 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PTGS2; ABCC1; ABCC1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; MAOA; MAOA; HCAR2; HTR2C; HTR2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; OPRD1; ACHE; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM; HTR2C |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; HTR2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |